Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M Kadia,Rashmi Malla,Naval Daver,Courtney D Dinardo,Marina Konopleva,Koji Sasaki,Ghayas C Issa,Kapil N Bhalla,Mark Brandt,Gautam Borthakur,Elias Jabbour,Nicholas J Short,Koichi Takahashi,Maro Ohanian,Nitin Jain,Kelly Marek,Hagop M Kantarjian,Michael Andreeff,Alessandra Ferrajoli,Naveen Pemmaraju,Farhad Ravandi,Jorge E Cortés ,Uday Popat ,Guillermo Garcia‐Manero ,Rashmi Kanagal‐Shamanna ,Guillermo Montalbán Bravo

doi:10.1182/blood-2020-142092

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M Kadia, Rashmi Malla + Show 24 more

Open Access

https://doi.org/10.1182/blood-2020-142092

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 11

Affiliation: The University of Texas MD Anderson Cancer Center, Augusta University Health

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Full Text